Race Oncology welcomes positive pre-IND meeting for Zantrene

Digital Asset Direct by Race Oncology Ltd

Melbourne, Victoria | November 24, 2022 11:20 AM Eastern Standard Time

Race Oncology Ltd (ASX:RAC) chief scientific officer Dr Daniel Tillett speaks with Proactive soon after receiving confidential and constructive guidance during a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for its asset Zantrene (bisantrene dihydrochloride). An IND is the prerequisite to clinical trials in the United States and a key step in the process of obtaining a new drug application (NDA) and marketing approval for a new drug.

Contact Details

Gregg Castano

+1 203-762-5649

gregg.castano@newsdirect.com